Emil J. Freireich - Concepedia

Author

Emil J. Freireich

The University of Texas MD Anderson Cancer Center

Also Known As

ACUTE LEUKEMIA GROUP B, E Freireich, E J FREIREICH, E J Freireich, E. Freireich, E. J Freireich, E. J. FREIREICH, E. J. Freireich, E.J Freireich, E.J. Freireich

665

Publications

33.6K

Citations

H-Index

266

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Anderson Hospital The University of Texas System National Institutes of Health The University of Texas Health Science Center at Houston

About

Emil J. Freireich is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	71	212	16.6K
2	Health Sciences	40	70	4.4K
3	Natural Sciences	6	6	540
4	Engineering	5	5	80
5	Nursing	2	2	111

Emil J. Freireich

350

Publications

31.4K

Citations

H-Index

Page 1

	Year	Citations
Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Emil J. Freireich, E. A. Gehan, David P. Rall, PubMed Comparative ToxicologyQuantitative ComparisonMedicinePharmacologyPathology	1966	1.4K
Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia Hagop M. Kantarjian, Susan O’Brien, Terry L. Smith, Journal of Clinical Oncology	2000	788
Reduction of Doxorubicin Cardiotoxicity by Prolonged Continuous Intravenous Infusion Sewa S. Legha, Robert S. Benjamin, Bruce R. MacKay, Annals of Internal Medicine	1982	767
Flow cytometry in clinical cancer research. Barthel Barlogie, Martin N. Raber, Johannes Schumann, PubMed Hematological MalignancyTumor BiologyFlow CytometryHormone Receptor ExpressionMalignant Disease	1983	766
Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes Álvaro Aguayo, Hagop M. Kantarjian, Taghi Manshouri, Blood	2000	657
Long‐term follow‐up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper‐CVAD), a dose‐intensive regimen, in adult acute lymphocytic leukemia Hagop M. Kantarjian, Deborah A. Thomas, Susan O’Brien, Cancer	2004	624
Rituximab Dose-Escalation Trial in Chronic Lymphocytic Leukemia Susan O’Brien, Hagop M. Kantarjian, Deborah A. Thomas, Journal of Clinical Oncology	2001	588
The Quantitative Relation between Platelet Count and Hemorrhage in Patients with Acute Leukemia Lawrence A. Gaydos, Emil J. Freireich, Nathan Mantel New England Journal of Medicine ThrombopoiesisThrombosisBacterial PolysaccharideBlood PlateletCoagulation Defects Disturbances	1962	532
Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia Philip A. Thompson, Constantine S. Tam, Susan O’Brien, Blood	2015	498
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System Hagop M. Kantarjian, Susan O’Brien, Farhad Ravandi, Cancer	2008	484

Page 1